Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Molecular profiling leading to personalized treatment in breast cancer

Molecular profiling leading to personalized treatment in breast cancer short review memo https://doi.org/10.1007/s12254-021-00792-4 Molecular profiling leading to personalized treatment in breast cancer Eva Valentina Klocker · Marija Balic · Günther Steger Received: 6 October 2021 / Accepted: 16 December 2021 © The Author(s) 2022 Summary With the development of various targeted ment, molecular profiling for already established therapies in breast cancer, detection of biomarkers for biomarkers is needed. Various technologies have predicting treatment efficacy gains importance. With been established, covering a wide range of recog- the definition of intrinsic subtypes, breast cancer has nized targets along with potential further biomarkers, paved the way for personalized treatment. Already such as next generation sequencing (NGS) or ribonu- known and recently recognized targets play an im- cleic acid(RNA)-based profiling or analyzing specific portant role both in metastatic and early breast can- targets with polymerase chain reaction (PCR) based cer. As a result, early molecular profiling is becoming assays. In addition, well-preserved tumor tissue for a part of early diagnostic work-up. Notwithstanding, testing is important. Defining treatment targets en- further treatment targets and agents are needed, par- ables the administration of efficient agents beyond ticularly in the most aggressive subtype encompassing chemotherapy. heterogenous diseases under the group of triple neg- ative breast cancer. Intrinsic subtypes and role of prognostic tests Keywords Molecular signature ·Targeted therapy · The classical stratification into the four subgroups lu- Biomarkers · Breast cancer · Next generation minal A, luminal B, human epidermal growth factor sequencing receptor 2 positive (HER2+) and triple negative is still crucial in the treatment of breast cancer. In addi- tion to definition of the subtype, in hormone receptor Breast cancer is the most common tumor in women positive (HR+), HER2– BC the estimation of risk for re- and the second most common cause for cancer-re- currence is important for treatment decisions. Several lated death in women [1]. During the last decades, tools dealing with gene signatures have been devel- various treatment targets have been defined and oped to date. One of the signatures, PAM 50, estimates have enabled efficient therapeutic strategies in breast the intrinsic subtype by the gene signature and pro- cancer (BC). In order to offer the most suitable treat- vides additional prognostic information [2]. Oncotype includes 21 genes for the prediction of the recurrence risk and enables the stratification into three groups: Dr. med. univ. E. V. Klocker ()· low, intermediate and high risk [3]. Sparrano et al. Assoz. Prof. PD Dr. med. univ. et scient. med. M. Balic randomized 6711 patients with HR+, HER2–, lymph Department of Oncology, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria node negative (N–) breast cancer with an intermediate eva.klocker@medunigraz.at recurrence score of 11–25 between chemotherapy plus endocrine treatment and endocrine treatment alone Assoz. Prof. PD Dr. med. univ. et scient. med. M. Balic in a prospective trial. In the total cohort no bene- marija.balic@medunigraz.at fit from adding adjuvant chemotherapy in interme- Univ.-Prof. Dr. G. Steger diate risk patients was shown. Nonetheless, women Department of Internal Medicine I, Division of ≤ 50 years old with a recurrence score of 16–25 re- Oncology, Medical University of Vienna, Waehringer ceiving chemotherapy in combination with endocrine Guertel 18–20, 1090 Vienna, Austria guenther.steger@meduniwien.ac.at K Molecular profiling in breast cancer short review therapy were more likely to show a benefit in disease- under evaluation [15]. Patritumab deruxtecan showed free survival (DFS) [4]. efficacy and tolerability in a phase 1 study including 21 pretreated metastatic breast cancer patients [16]. This ADC showed also promising results in a phase Challenging the definition of intrinsic subtypes 1 study in nonsmall cell lung cancer, especially in pa- tients with higher HER3 expression [17]. However, tar- HER2 low geting HER3 in breast cancer is still a future goal and The transmembrane tyrosine kinase receptor HER2 needs to be studied further. represents a well-established treatment target. HER2 positivity is defined by the American Society of Clin- TNBC ical Oncology/College of American Pathologist as immunohistochemistry (IHC)+++ [5]. In tissues with TNBC lacking estrogen receptor (ER)–, progesteron IHC++, meaning a weak to moderate membrane receptor (PR)–, and HER2 remains a treatment chal- staining in > 10% of tumor cells, a reflex in situ hy- lenge. As shown by Burstein et al. and others, TNBC bridization (ISH) is recommended [5]. If tissue is is a heterogeneous disease. Burstein et al. defined IHC 0 or IHC+, the result is HER2 negative (HER2–) 4 TNBC subtypes using a PAM50 gene signature: lu- [5]. However, HER2 low is IHC+ or IHC++ with a neg- minal androgen receptor (LAR), mesenchymal (MES), ative ISH result. basal-like immunosuppressed (BLIS) and basal-like Due to the development of antibody–drug conju- immune activated (BLIA) [18]. Androgen-receptor gates (ADCs), HER2 low has reached a new signifi- (AR) might represent a treatment target, as AR– in- cance. ADC trastzumab–deruxtecan (T-Dx) shows ef- hibitors were studied in AR expressing TNBC and fectiveness in HER2+, HER2 low and also in HER2 het- showed clinical response [19]. The recently developed erogeneous BC by the bystander killing effect [6–8]. ADC sacituzumab–govitecan, targeting the antithro- The phase III trial was presented at ESMO 2021 and phoblast cell–surface antigen 2 (TROP2) has shown a significantly longer DFS and overall survival (OS) promising results in heavily pretreated patients with compared to trastuzumab-emtansine (T-DM1) in sec- TNBC [20]. Further studies in triple negative and ond line was detected in HER2+ mBC patients [9]. also HER2-BC are ongoing. To date, no selection by Phase III trials are ongoing in HER2 low patients. TROP2 expression is needed due to the bystander Another second-generation antibody conjugate killing effect, but the efficacy is clearly correlated with targeting HER2 is SYD958, called trastuzumab duo- the level of TROP2 expression. carmazine, with an ongoing phase III study TULIP, which showed promising results in the first analysis Potential of liquid biopsy presented at ESMO 2021[10]. It showed efficacy in heavily pretreated, HER2+, HER2 low, and T-DM1 Over the last decade, an increasing number of tech- resistant breast cancers in a phase I trial [11]. nologies to comprehensively analyze circulating de- oxyribonucleic acid (DNA) and particularly the tu- mor fraction have evolved and now various possibil- HER2 mutations ities for mutation testing are provided [21–23]. The Beyond HER2 low BC, ERB2 mutations remain a treat- phase 2a plasmaMATCH trial selected patients for ment challenge. HER2 mutationsfunction asdriver specific treatment based on detection of mutations mutations in tumors without an amplification of in circulating tumor DNA. The sensitivity and speci- HER2 too [12]. Tyrosine kinase inhibitors, such as ficity in the circulating tumor DNA were comparable HER2 targeting neratinib are able to directly inhibit with mutation testing in tumor tissue for protein intracellular signaling and have demonstrated their kinase B 1 (AKT1), HER2, and phosphoinositide-3-ki- efficacy in HER2 mutations [13]. nase, catalytic, alpha polypeptide (PIK3CA) mutations [21]. This trial paved the way for future personalized oncology approaches. HER3 Another example in endocrine therapy-resistant As HER2 needs another member of the ERB family to breast cancers is the acquired estrogen receptor 1 build heterodimers for signaling, human epidermal (ESR1) mutation [24, 25]. The detection of ESR1 growth factor receptor 3 (HER3) plays a role in HER2+ mutation in plasma after progression on aromatase breast cancers. HER3 appears to be a part of an es- inhibitor could be used for endocrine treatment de- cape mechanism in HER2 targeting treatments. As cision [23]. Fulvestrant has shown efficacy in ESR1- a result, HER3 and its mechanisms in signaling have mutated breast cancer [23] and clinical trials are now been widely studied. There is evidence that HER3 testing the hypothesis in larger patient cohorts. is essential for the HER2 driven phosphatidylinosi- tol 3-kinase-protein kinase B (PI3K-AKT) pathway by binding heterodimers with HER2 [14]. The ADC patri- tumab deruxtecan which specifically binds to HER3 is Molecular profiling in breast cancer K short review Table 1 Therapeutic agents and their targets Target Setting Therapeutic agent Germline mBCRA1/2 Adjuvant, palliative PARP inhibitors HER2 Neoadjuvant, adjuvant, Trastuzumab, pertuzumab, palliative neratinib, lapatinib, tucatinib, T-DM1, T-Dx HER2 mutations Palliative Neratinib, lapatinib, tucatinib HER2 low/HER2 heterogeneity In development palliative T-Dx HR Neoadjuvant, adjuvant, SERM, AI palliative PIK3CA Palliative Alpelisib PD-L1/CPS Palliative, neoadjuvant? Atezolizumab, pembrolizumab PTEN, AKT Palliative? AKT inhibitors? TROP2? Palliative Sacituzumab–govitecan HER2 Human epidermal growth factor receptor 2, HR hormone receptor, PIK3CA phosphoinositide-3-kinase, catalytic, alpha polypeptide, PD-L1 Programmed death-ligand 1, CPS combined positive score, PTEN phosphatase and tensin homolog, AKT protein kinase B, TROP2 antithrophoblast cell–surface antigen 2, T-DM1 trastuzumab–emtansine, T-Dx trastuzumab–deruxtecan, SERM selective estrogen receptor modulators, AI aromatase inhibitors Biomarkers with therapeutic relevance BRCA 1/2 mutation Besides the well-known HR and HER2 status, which In HER2– disease, PARP inhibitors represent an ac- became relevant during the 1990s, more biomarkers tive agent in germline-mutated BRreat CAncer gene have gained therapeutic importance (Table 1). (BRCA1/2) mBC [32, 33]. In mBC PARP inhibitors sig- nificantly prolong PFS [32, 33]. No significant im- pact in overall survival (OS) has been be detected. PIK3CA mutation In ovarian cancer these agents are effective in both The establishment of alpelisib in the therapy algo- germline and somatic mutations [34]. However, the rithm of PIK3CA-mutated metastatic HR+, HER2– BC role of somatic BRCA1/2 mutations or “BRCAness” in requires testing for this mutation [26]. Although the BC is not fully clarified to this date. In the GeparOLA PIK3CA mutation is an early mutation, an acquired trial, for example, germline and somatic BRCA1/2 and PIK3CA mutation may occur under CDK4/6 inhibitor additional mutations leading to homologous recom- treatment associated with resistance to these drugs binant deficiency were included [35]. The effect of [24]. While the SOLAR trial demonstrated efficacy of olaparib as an additional neoadjuvant agent was su- alpelisib particularly in PIK3CA-mutated patients [27], perior only in germline-mutated BRCA1/2 patients in in the BYlieve trial alpelisib showed a significant im- the HR+ and in the < 40 years subgroups [35]. An- pact on progression free survival (PFS) after progress other trial including germline mutations, somatic mu- on CDK4/6 [22]. In this trial, PIK3CA mutation test- tations, BRCA1/2 methylation status and BRCA 1/2 ing was done by NGS or PCR in circulating DNA in messenger RNA (mRNA) analyzing the effect of carbo- addition to tumor tissue [22]. platin versus docetaxel in metastatic setting showed an effect of carboplatin solely in the germline-mu- tated cohort [36]. Nonetheless, only a small num- PI3K/AKT pathway ber of patients revealed a germline mutation in this Changes in the PI3K/AKT pathway like phosphatase study. The significance of somatic BRCA1/2 muta- and tensin homolog (PTEN) loss or hyperactivated tions ora “BRCAnesstype” fortreatment in BC has not AKT represent potentially useful treatment targets yet been confirmed. Further studies are needed, and [28]. The PI3K/AKT signaling pathway plays an im- one of the trials is the ABCSG45 neoadjuvant phase II portant role in breast cancer. PTEN possesses an study evaluating the combination of carboplatin and inhibiting role, whereas AKT holds an activating func- olaparib versus standard neoadjuvant chemotherapy tion. The AKT inhibitors capivasertib and ipatasertib in patients with “BRCAness”. Germline BCRA1/2 mu- showed promising results in the phase II trials LOTUS tation testing is becoming an imperative for TNBC and and FAKTION [29, 30]. However, the phase III trial high-risk hormone receptor positive BC patients in IPATunity130 with ipatasertib in combination with the adjuvant setting based on the adjuvant OlympiaD paclitaxel in metastatic TNBC (mTNBC) failed to con- trial. Administration of olaparib for 1 year after fin- firm its benefit [31]. A biomarker analysis of the ishing adjuvant/neoadjuvant treatment in high risk IPATunity130 is planned and may provide additional germline-mutated BRCA1/2 patients leads to an im- information about the subgroups. However, the first proved invasive disease-free survival (iDFS) [37]. results of the phase III trial analyzing capivasertib in this setting are not yet available. K Molecular profiling in breast cancer short review References PD-L1 and CPS score 1. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. A clinically established biomarker beyond germline CACancerJClin. 2021;71(1):7–33. https://doi.org/10.3322/ BRCA1/2 mutation status for treatment decision in caac.21654. Erratumin: CA Cancer J Clin. 2021;71(4):359. TNBC is the programmed death-ligand 1 (PD-L1) sta- 2. Parker JS, Mullins M, Cheang MCU, et al. Supervised risk tus [38, 39]. In mTNBC the addition of atezolizumab predictorofbreastcancerbasedonintrinsicsubtypes. JClin to nab–paclitaxel significantly prolonged PFS and im- Oncol. 2009;27(8):1160–7. proved median OS in PD-L1 positive patients [38]. PD- 3. Paik S, Kim C,Baehner FL,et al. AMultigene assayto predict recurrence of Tamoxifen-treated, node-negative L1 positivity was defined as PD-L1 expression in im- breastcancer. NEngl J Med. 2004;351(27):2817–26. mune cells that covers ≥ 1% of the tumor and was as- 4. Sparano JA, Gray RJ, Makower DF, et al. Adjuvant sessed using the SP142 PD-L1 immunohistochemical chemotherapy guided by a 21-gene expression assay in assay (Ventana) [38]. In the KEYNOTE-355, the addi- breastcancer. NEngl J Med. 2018;379(2):111–21. tion of pembrolizumab improved PFS in patients with 5. Wolff AC, Hammond MEH, Allison KH, et al. Human a combined positive score (CPS) ≥ 10 [39]. In contrast, epidermal growth factor receptor 2 testing in breast cancer: the role of the PD-L1 status in the neoadjuvant setting AmericanSocietyofClinicalOncology/CollegeofAmerican Pathologists Clinical practice guideline focused update. is less prominent, since the benefit of pembrolizumab J Clin Oncol. 2018;36(20):2105–22. or atezolizumab was shown independently from the 6. Modi S, Saura C, Yamashita T, et al. Trastuzumab Derux- PD-L1 status [40, 41]. tecan in previously treated HER2-positive breast cancer. To sum up, with the development of novel targeted NEngl J Med. 2020;382(7):610–21. therapies, molecular profiling is gaining in impor- 7. Ogitani Y, Hagihara K, Oitate M, et al. Bystander killing tance. Whereas an increasing number of molecularly effect of DS-8201a, a novel anti-human epidermal growth factorreceptor2antibody—Drugconjugate,intumorswith driven clinical trials is becoming available, it is in- human epidermal growth factor receptor 2 heterogeneity. creasingly difficult for clinical trials to represent the Cancer Sci. 2016;107(7):1039. heterogeneity of breast cancer biology. Nevertheless, 8. Modi S, Park H, Murthy RK, et al. Antitumor activity in today’s clinical practice biomarker testing, it is and safety of Trastuzumab Deruxtecan in patients with a prerequisite to adequately treat breast cancer pa- HER2-low-expressing advancedbreastcancer: results from tients. Analysis of established biomarkers in BC is a phaseIbstudy. J Clin Oncol. 2020;38(17):1887. essentialfor allpatients where treatment is available. 9. Cortes J, Kim S, Chung W, et al. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients Currently, it is still recommended to perform biopsies (Pts) with HER2+ metastatic breast cancer (mBC): Results of new lesions in metastatic patients. The hope is that of the randomized phase III DESTINY-Breast03 study. Ann with the increasing number of studies, cell free DNA Oncol. 2021;32(suppl_5):S1283–S346. https://doi.org/10. based mutation testing will demonstrate its reliability 1016/annonc/annonc741.abstrLBA1. and robustness and at least partially replace the more 10. Manich SC, O’Shaughnessy J, Aftimos PG, et al. Primary invasive tissue testing. With the available novel tech- outcome of the phase III SYD985.002/TULIP trial compar- nologies, the hope is to identify an increasing number ing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive lo- of treatment targets and agents which are urgently cally advanced or metastatic breast cancer. Ann Oncol. needed especially for TNBC. 2021;32(suppl_5):S1283–S346. https://doi.org/10.1016/ Funding Open access funding provided by Medical University annonc/annonc741. abstr LBA15. of Graz. 11. Banerji U, van Herpen CML, Saura C, et al. Trastuzumab duocarmazine in locally advanced and metastatic solid Conflict of interest E.V. Klocker received congress fees from tumours and HER2-expressing breast cancer: a phase 1 Pierre Fabre, Roche and Daiichi-Sankyo and congress fees dose-escalation and dose-expansion study. Lancet Oncol. from Novartis and AstraZeneca. M. Balic received honoraria 2019;20(8):1124–35. and congress fees from Amgen, AstraZeneca, Bayer, Celgene, 12. Bose R, Kavuri SM, Searleman AC, et al. Activating HER2 Daichii Sankyo, Pfizer, EliLilly, Novartis, Roche, MSD, Sam- mutations in HER2 gene amplification negative breast sung, Pierre Fabre and Seagen. G. Steger declares that he has cancer. Cancer Discov. 2013;3(2):224–37. no competing interests. 13. HymanDM, Piha-Paul SA, WonH,et al. HERkinase inhi- bition in patients with HER2- and HER3-mutant cancers. Open Access This article is licensed under a Creative Com- Nature. 2018;554(7691):189–94. mons Attribution 4.0 International License, which permits 14. Dey N, Williams C, Leyland-Jones B, et al. A critical role use, sharing, adaptation, distribution and reproduction in for HER3 in HER2-amplified and non-amplified breast any medium or format, as long as you give appropriate credit cancers: function of a kinase-dead RTK. Am J Transl Res. to the original author(s) and the source, provide a link to 2015;7(4):733–50. the Creative Commons licence, and indicate if changes were 15. Pascual T, Oliveira M, Ciruelos E, et al. SOLTI-1805 TOT- made. The images or other third party material in this article HER3 study concept: a window-of-opportunity trial of are included in the article’s Creative Commons licence, unless Patritumab Deruxtecan, a HER3 directed antibody drug indicated otherwise in a credit line to the material. If material conjugate, in patients with early breast cancer. Front Oncol. is not included in the article’s Creative Commons licence and 2021;11:638482. your intended use is not permitted by statutory regulation or 16. Kogawa T, Yonemori K, Masuda N, etal. Singleagentactivity exceeds the permitted use, you will need to obtain permis- of U3-1402, a HER3-targeting antibody-drug conjugate, in sion directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. Molecular profiling in breast cancer K short review breast cancer patients: Phase 1 dose escalation study. J Clin Primary results from IPATunity130 Cohort A. Cancer Res. Oncol. 2018;36(15_suppl):2512–2512. 2021;81(4_Suppl):abstr GS3-04. SABCS20-GS3-04. 17. Janne PA, Baik C, Su WC, et al. Efficacy and safety of 32. Robson M, Im SA, Senkus E, et al. Olaparib for metastatic Patritumab Deruxtecan (HER3-DXd) in EGFR inhibitor-re- breast cancer in patients with a Germline BRCA mutation. sistant, EGFR-mutated non-small cell lung cancer. Cancer NEngl J Med. 2017;377(6):523–33. Discov. 2021; 2022 Jan;12(1):74–89. 33. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with 18. Burstein MD, Tsimelzon A, Poage GM, et al. Compre- advanced breast cancer and a Germline BRCA mutation. hensive genomic analysis identifies novel subtypes and NEngl J Med. 2018;379(8):753–63. targets of triple-negative breast cancer. Clin Cancer Res. 34. Tomao F, Bardhi E, Di Pinto A, et al. Parp inhibitors as 2015;21(7):1688–98. maintenance treatment in platinum sensitive recurrent 19. Traina TA, Miller K, Yardley DA, et al. Enzalutamide for the ovarian cancer: an updated meta-analysis of randomized treatment of androgen receptor-expressing triple-negative clinical trials according to BRCA mutational status. Cancer breastcancer. J Clin Oncol. 2018;36(9):884–90. TreatRev. 2019;80:101909. 20. BardiaA,HurvitzSA,TolaneyAM,etal. Sacituzumabgovite- 35. Fasching PA, Link T, Hauke J, Seither F, Jackisch C, Klare P, can in metastatic triple-negative breast cancer. N Engl J et al. Neoadjuvant paclitaxel/olaparib in comparison to Med. 2021;384:1529–41. paclitaxel/carboplatinum in patients with HER2-negative 21. TurnerNC,KingstonB,KilburnLS,etal. Circulatingtumour breast cancer and homologous recombination deficiency DNA analysis to direct therapy in advanced breast cancer (GeparOLA study). Ann Oncol. 2021;32(1):49–57. (plasmaMATCH): a multicentre, multicohort, phase 2a, 36. Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, platformtrial. LancetOncol. 2020;21(10):1296–308. Gazinska P, et al. Carboplatin in BRCA1/2-mutated and 22. Rugo HS, Lerebours F, Ciruelos E, et al. Alpelisib plus ful- triple-negative breast cancer BRCAness subgroups: the vestrant in PIK3CA-mutated, hormone receptor-positive TNT Trial. NatMed. 2018;24(5):628–37. advanced breast cancer after a CDK4/6 inhibitor (BYLieve): 37. Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, one cohort of a phase 2, multicentre, open-label, non- Rastogi P, et al. Adjuvant Olaparib for patients with comparativestudy. LancetOncol. 2021;22(4):489–98. BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 23. Fribbens C, O’Leary B, Kilburn L, et al. Plasma ESR1 2021;384(25):2394–405. mutations and the treatment of estrogen receptor-positive 38. Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab- advancedbreastcancer. J Clin Oncol. 2016;34(25):2961–8. paclitaxel as first-line treatment for unresectable, locally 24. O’Leary B, Cutts RJ, Liu Y, et al. The genetic landscape and advanced or metastatic triple-negative breast cancer (IM- clonal evolution of breast cancer resistance to Palbociclib passion130): updated efficacy results from a randomised, plus Fulvestrant in the PALOMA-3 trial. Cancer Discov. double-blind, placebo-controlled, phase 3 trial. Lancet 2018;8(11):1390–403. Oncol. 2020;21(1):44–59. 25. Razavi P, Chang MT, Xu G, et al. The genomic landscape of 39. Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab endocrine-resistant advanced breast cancers. Cancer Cell. plus chemotherapy versus placebo plus chemotherapy 2018; 34(3):427–438.e6. for previously untreated locally recurrent inoperable or 26. AndréF,CiruelosE,RubovszkyG,etal. AlpelisibforPIK3CA- metastatic triple-negative breast cancer (KEYNOTE-355): mutated, hormone receptor-positive advanced breast can- a randomised, placebo-controlled, double-blind, phase 3 cer. NEngl J Med. 2019;380(20):1929–40. clinical trial. Lancet. 2020;396(10265):1817–28. 27. André F, Ciruelos EM, Juric D, et al. Alpelisib plus ful- 40. Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab vestrant for PIK3CA-mutated, hormone receptor-positive, for early triple-negative breast cancer. N Engl J Med. human epidermal growth factor receptor-2-negative ad- 2020;382(9):810–21. vanced breast cancer: final overall survival results from 41. Mittendorf EA, Zhang H, Barrios CH, etal. Neoadjuvantate- SOLAR-1. Ann Oncol. 2021;32(2):208–17. zolizumab in combination with sequential nab-paclitaxel 28. Lin J, Sampath D, Nannini MA, et al. Targeting activated and anthracycline-based chemotherapy versus placebo Akt with GDC-0068, a novel selective akt inhibitor that is and chemotherapy in patients with early-stage triple-nega- efficacious in multiple tumor models. Clin Cancer Res. tive breast cancer (IMpassion031): a randomised, double- 2013;19(7):1760–72. blind, phase3 trial. Lancet. 2020;396(10257):1090–100. 29. Jones RH, CasbardA, Carucci M, etal. Fulvestrantplus capi- Publisher’s Note Springer Nature remains neutral with regard vasertib versus placebo after relapse or progression on an to jurisdictional claims in published maps and institutional aromatase inhibitor in metastatic, oestrogen receptor-pos- affiliations. itive breast cancer (FAKTION): a multicentre, randomised, controlled, phase2 trial. LancetOncol. 2020;21(3):345–57. 30. Kim SB, Dent R, Im SA, et al. Ipatasertib plus pacli- taxel versus placebo plus paclitaxel as first-line therapy for 7 For latest news from interna- metastatic triple-negative breast cancer (LOTUS): a mul- ticentre, randomised, double-blind, placebo-controlled, tional oncology congresses see: phase2 trial. LancetOncol. 2017;18(10):1360–72. http://www.springermedizin.at/ 31. Dent R, Kim SB, Oliveira M, et al. Double-blind memo-inoncology placebo-controlled randomized phase III trial evalu- ating first-line ipatasertib combined with paclitaxel for -PIK3CA/AKT1/PTEN-altered locally advanced un- resectable or metastatic triple-negative breast cancer: K Molecular profiling in breast cancer http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Molecular profiling leading to personalized treatment in breast cancer

Loading next page...
 
/lp/springer-journals/molecular-profiling-leading-to-personalized-treatment-in-breast-cancer-hDzk3ugHt0
Publisher
Springer Journals
Copyright
2022 The Author(s)
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-021-00792-4
Publisher site
See Article on Publisher Site

Abstract

short review memo https://doi.org/10.1007/s12254-021-00792-4 Molecular profiling leading to personalized treatment in breast cancer Eva Valentina Klocker · Marija Balic · Günther Steger Received: 6 October 2021 / Accepted: 16 December 2021 © The Author(s) 2022 Summary With the development of various targeted ment, molecular profiling for already established therapies in breast cancer, detection of biomarkers for biomarkers is needed. Various technologies have predicting treatment efficacy gains importance. With been established, covering a wide range of recog- the definition of intrinsic subtypes, breast cancer has nized targets along with potential further biomarkers, paved the way for personalized treatment. Already such as next generation sequencing (NGS) or ribonu- known and recently recognized targets play an im- cleic acid(RNA)-based profiling or analyzing specific portant role both in metastatic and early breast can- targets with polymerase chain reaction (PCR) based cer. As a result, early molecular profiling is becoming assays. In addition, well-preserved tumor tissue for a part of early diagnostic work-up. Notwithstanding, testing is important. Defining treatment targets en- further treatment targets and agents are needed, par- ables the administration of efficient agents beyond ticularly in the most aggressive subtype encompassing chemotherapy. heterogenous diseases under the group of triple neg- ative breast cancer. Intrinsic subtypes and role of prognostic tests Keywords Molecular signature ·Targeted therapy · The classical stratification into the four subgroups lu- Biomarkers · Breast cancer · Next generation minal A, luminal B, human epidermal growth factor sequencing receptor 2 positive (HER2+) and triple negative is still crucial in the treatment of breast cancer. In addi- tion to definition of the subtype, in hormone receptor Breast cancer is the most common tumor in women positive (HR+), HER2– BC the estimation of risk for re- and the second most common cause for cancer-re- currence is important for treatment decisions. Several lated death in women [1]. During the last decades, tools dealing with gene signatures have been devel- various treatment targets have been defined and oped to date. One of the signatures, PAM 50, estimates have enabled efficient therapeutic strategies in breast the intrinsic subtype by the gene signature and pro- cancer (BC). In order to offer the most suitable treat- vides additional prognostic information [2]. Oncotype includes 21 genes for the prediction of the recurrence risk and enables the stratification into three groups: Dr. med. univ. E. V. Klocker ()· low, intermediate and high risk [3]. Sparrano et al. Assoz. Prof. PD Dr. med. univ. et scient. med. M. Balic randomized 6711 patients with HR+, HER2–, lymph Department of Oncology, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria node negative (N–) breast cancer with an intermediate eva.klocker@medunigraz.at recurrence score of 11–25 between chemotherapy plus endocrine treatment and endocrine treatment alone Assoz. Prof. PD Dr. med. univ. et scient. med. M. Balic in a prospective trial. In the total cohort no bene- marija.balic@medunigraz.at fit from adding adjuvant chemotherapy in interme- Univ.-Prof. Dr. G. Steger diate risk patients was shown. Nonetheless, women Department of Internal Medicine I, Division of ≤ 50 years old with a recurrence score of 16–25 re- Oncology, Medical University of Vienna, Waehringer ceiving chemotherapy in combination with endocrine Guertel 18–20, 1090 Vienna, Austria guenther.steger@meduniwien.ac.at K Molecular profiling in breast cancer short review therapy were more likely to show a benefit in disease- under evaluation [15]. Patritumab deruxtecan showed free survival (DFS) [4]. efficacy and tolerability in a phase 1 study including 21 pretreated metastatic breast cancer patients [16]. This ADC showed also promising results in a phase Challenging the definition of intrinsic subtypes 1 study in nonsmall cell lung cancer, especially in pa- tients with higher HER3 expression [17]. However, tar- HER2 low geting HER3 in breast cancer is still a future goal and The transmembrane tyrosine kinase receptor HER2 needs to be studied further. represents a well-established treatment target. HER2 positivity is defined by the American Society of Clin- TNBC ical Oncology/College of American Pathologist as immunohistochemistry (IHC)+++ [5]. In tissues with TNBC lacking estrogen receptor (ER)–, progesteron IHC++, meaning a weak to moderate membrane receptor (PR)–, and HER2 remains a treatment chal- staining in > 10% of tumor cells, a reflex in situ hy- lenge. As shown by Burstein et al. and others, TNBC bridization (ISH) is recommended [5]. If tissue is is a heterogeneous disease. Burstein et al. defined IHC 0 or IHC+, the result is HER2 negative (HER2–) 4 TNBC subtypes using a PAM50 gene signature: lu- [5]. However, HER2 low is IHC+ or IHC++ with a neg- minal androgen receptor (LAR), mesenchymal (MES), ative ISH result. basal-like immunosuppressed (BLIS) and basal-like Due to the development of antibody–drug conju- immune activated (BLIA) [18]. Androgen-receptor gates (ADCs), HER2 low has reached a new signifi- (AR) might represent a treatment target, as AR– in- cance. ADC trastzumab–deruxtecan (T-Dx) shows ef- hibitors were studied in AR expressing TNBC and fectiveness in HER2+, HER2 low and also in HER2 het- showed clinical response [19]. The recently developed erogeneous BC by the bystander killing effect [6–8]. ADC sacituzumab–govitecan, targeting the antithro- The phase III trial was presented at ESMO 2021 and phoblast cell–surface antigen 2 (TROP2) has shown a significantly longer DFS and overall survival (OS) promising results in heavily pretreated patients with compared to trastuzumab-emtansine (T-DM1) in sec- TNBC [20]. Further studies in triple negative and ond line was detected in HER2+ mBC patients [9]. also HER2-BC are ongoing. To date, no selection by Phase III trials are ongoing in HER2 low patients. TROP2 expression is needed due to the bystander Another second-generation antibody conjugate killing effect, but the efficacy is clearly correlated with targeting HER2 is SYD958, called trastuzumab duo- the level of TROP2 expression. carmazine, with an ongoing phase III study TULIP, which showed promising results in the first analysis Potential of liquid biopsy presented at ESMO 2021[10]. It showed efficacy in heavily pretreated, HER2+, HER2 low, and T-DM1 Over the last decade, an increasing number of tech- resistant breast cancers in a phase I trial [11]. nologies to comprehensively analyze circulating de- oxyribonucleic acid (DNA) and particularly the tu- mor fraction have evolved and now various possibil- HER2 mutations ities for mutation testing are provided [21–23]. The Beyond HER2 low BC, ERB2 mutations remain a treat- phase 2a plasmaMATCH trial selected patients for ment challenge. HER2 mutationsfunction asdriver specific treatment based on detection of mutations mutations in tumors without an amplification of in circulating tumor DNA. The sensitivity and speci- HER2 too [12]. Tyrosine kinase inhibitors, such as ficity in the circulating tumor DNA were comparable HER2 targeting neratinib are able to directly inhibit with mutation testing in tumor tissue for protein intracellular signaling and have demonstrated their kinase B 1 (AKT1), HER2, and phosphoinositide-3-ki- efficacy in HER2 mutations [13]. nase, catalytic, alpha polypeptide (PIK3CA) mutations [21]. This trial paved the way for future personalized oncology approaches. HER3 Another example in endocrine therapy-resistant As HER2 needs another member of the ERB family to breast cancers is the acquired estrogen receptor 1 build heterodimers for signaling, human epidermal (ESR1) mutation [24, 25]. The detection of ESR1 growth factor receptor 3 (HER3) plays a role in HER2+ mutation in plasma after progression on aromatase breast cancers. HER3 appears to be a part of an es- inhibitor could be used for endocrine treatment de- cape mechanism in HER2 targeting treatments. As cision [23]. Fulvestrant has shown efficacy in ESR1- a result, HER3 and its mechanisms in signaling have mutated breast cancer [23] and clinical trials are now been widely studied. There is evidence that HER3 testing the hypothesis in larger patient cohorts. is essential for the HER2 driven phosphatidylinosi- tol 3-kinase-protein kinase B (PI3K-AKT) pathway by binding heterodimers with HER2 [14]. The ADC patri- tumab deruxtecan which specifically binds to HER3 is Molecular profiling in breast cancer K short review Table 1 Therapeutic agents and their targets Target Setting Therapeutic agent Germline mBCRA1/2 Adjuvant, palliative PARP inhibitors HER2 Neoadjuvant, adjuvant, Trastuzumab, pertuzumab, palliative neratinib, lapatinib, tucatinib, T-DM1, T-Dx HER2 mutations Palliative Neratinib, lapatinib, tucatinib HER2 low/HER2 heterogeneity In development palliative T-Dx HR Neoadjuvant, adjuvant, SERM, AI palliative PIK3CA Palliative Alpelisib PD-L1/CPS Palliative, neoadjuvant? Atezolizumab, pembrolizumab PTEN, AKT Palliative? AKT inhibitors? TROP2? Palliative Sacituzumab–govitecan HER2 Human epidermal growth factor receptor 2, HR hormone receptor, PIK3CA phosphoinositide-3-kinase, catalytic, alpha polypeptide, PD-L1 Programmed death-ligand 1, CPS combined positive score, PTEN phosphatase and tensin homolog, AKT protein kinase B, TROP2 antithrophoblast cell–surface antigen 2, T-DM1 trastuzumab–emtansine, T-Dx trastuzumab–deruxtecan, SERM selective estrogen receptor modulators, AI aromatase inhibitors Biomarkers with therapeutic relevance BRCA 1/2 mutation Besides the well-known HR and HER2 status, which In HER2– disease, PARP inhibitors represent an ac- became relevant during the 1990s, more biomarkers tive agent in germline-mutated BRreat CAncer gene have gained therapeutic importance (Table 1). (BRCA1/2) mBC [32, 33]. In mBC PARP inhibitors sig- nificantly prolong PFS [32, 33]. No significant im- pact in overall survival (OS) has been be detected. PIK3CA mutation In ovarian cancer these agents are effective in both The establishment of alpelisib in the therapy algo- germline and somatic mutations [34]. However, the rithm of PIK3CA-mutated metastatic HR+, HER2– BC role of somatic BRCA1/2 mutations or “BRCAness” in requires testing for this mutation [26]. Although the BC is not fully clarified to this date. In the GeparOLA PIK3CA mutation is an early mutation, an acquired trial, for example, germline and somatic BRCA1/2 and PIK3CA mutation may occur under CDK4/6 inhibitor additional mutations leading to homologous recom- treatment associated with resistance to these drugs binant deficiency were included [35]. The effect of [24]. While the SOLAR trial demonstrated efficacy of olaparib as an additional neoadjuvant agent was su- alpelisib particularly in PIK3CA-mutated patients [27], perior only in germline-mutated BRCA1/2 patients in in the BYlieve trial alpelisib showed a significant im- the HR+ and in the < 40 years subgroups [35]. An- pact on progression free survival (PFS) after progress other trial including germline mutations, somatic mu- on CDK4/6 [22]. In this trial, PIK3CA mutation test- tations, BRCA1/2 methylation status and BRCA 1/2 ing was done by NGS or PCR in circulating DNA in messenger RNA (mRNA) analyzing the effect of carbo- addition to tumor tissue [22]. platin versus docetaxel in metastatic setting showed an effect of carboplatin solely in the germline-mu- tated cohort [36]. Nonetheless, only a small num- PI3K/AKT pathway ber of patients revealed a germline mutation in this Changes in the PI3K/AKT pathway like phosphatase study. The significance of somatic BRCA1/2 muta- and tensin homolog (PTEN) loss or hyperactivated tions ora “BRCAnesstype” fortreatment in BC has not AKT represent potentially useful treatment targets yet been confirmed. Further studies are needed, and [28]. The PI3K/AKT signaling pathway plays an im- one of the trials is the ABCSG45 neoadjuvant phase II portant role in breast cancer. PTEN possesses an study evaluating the combination of carboplatin and inhibiting role, whereas AKT holds an activating func- olaparib versus standard neoadjuvant chemotherapy tion. The AKT inhibitors capivasertib and ipatasertib in patients with “BRCAness”. Germline BCRA1/2 mu- showed promising results in the phase II trials LOTUS tation testing is becoming an imperative for TNBC and and FAKTION [29, 30]. However, the phase III trial high-risk hormone receptor positive BC patients in IPATunity130 with ipatasertib in combination with the adjuvant setting based on the adjuvant OlympiaD paclitaxel in metastatic TNBC (mTNBC) failed to con- trial. Administration of olaparib for 1 year after fin- firm its benefit [31]. A biomarker analysis of the ishing adjuvant/neoadjuvant treatment in high risk IPATunity130 is planned and may provide additional germline-mutated BRCA1/2 patients leads to an im- information about the subgroups. However, the first proved invasive disease-free survival (iDFS) [37]. results of the phase III trial analyzing capivasertib in this setting are not yet available. K Molecular profiling in breast cancer short review References PD-L1 and CPS score 1. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. A clinically established biomarker beyond germline CACancerJClin. 2021;71(1):7–33. https://doi.org/10.3322/ BRCA1/2 mutation status for treatment decision in caac.21654. Erratumin: CA Cancer J Clin. 2021;71(4):359. TNBC is the programmed death-ligand 1 (PD-L1) sta- 2. Parker JS, Mullins M, Cheang MCU, et al. Supervised risk tus [38, 39]. In mTNBC the addition of atezolizumab predictorofbreastcancerbasedonintrinsicsubtypes. JClin to nab–paclitaxel significantly prolonged PFS and im- Oncol. 2009;27(8):1160–7. proved median OS in PD-L1 positive patients [38]. PD- 3. Paik S, Kim C,Baehner FL,et al. AMultigene assayto predict recurrence of Tamoxifen-treated, node-negative L1 positivity was defined as PD-L1 expression in im- breastcancer. NEngl J Med. 2004;351(27):2817–26. mune cells that covers ≥ 1% of the tumor and was as- 4. Sparano JA, Gray RJ, Makower DF, et al. Adjuvant sessed using the SP142 PD-L1 immunohistochemical chemotherapy guided by a 21-gene expression assay in assay (Ventana) [38]. In the KEYNOTE-355, the addi- breastcancer. NEngl J Med. 2018;379(2):111–21. tion of pembrolizumab improved PFS in patients with 5. Wolff AC, Hammond MEH, Allison KH, et al. Human a combined positive score (CPS) ≥ 10 [39]. In contrast, epidermal growth factor receptor 2 testing in breast cancer: the role of the PD-L1 status in the neoadjuvant setting AmericanSocietyofClinicalOncology/CollegeofAmerican Pathologists Clinical practice guideline focused update. is less prominent, since the benefit of pembrolizumab J Clin Oncol. 2018;36(20):2105–22. or atezolizumab was shown independently from the 6. Modi S, Saura C, Yamashita T, et al. Trastuzumab Derux- PD-L1 status [40, 41]. tecan in previously treated HER2-positive breast cancer. To sum up, with the development of novel targeted NEngl J Med. 2020;382(7):610–21. therapies, molecular profiling is gaining in impor- 7. Ogitani Y, Hagihara K, Oitate M, et al. Bystander killing tance. Whereas an increasing number of molecularly effect of DS-8201a, a novel anti-human epidermal growth factorreceptor2antibody—Drugconjugate,intumorswith driven clinical trials is becoming available, it is in- human epidermal growth factor receptor 2 heterogeneity. creasingly difficult for clinical trials to represent the Cancer Sci. 2016;107(7):1039. heterogeneity of breast cancer biology. Nevertheless, 8. Modi S, Park H, Murthy RK, et al. Antitumor activity in today’s clinical practice biomarker testing, it is and safety of Trastuzumab Deruxtecan in patients with a prerequisite to adequately treat breast cancer pa- HER2-low-expressing advancedbreastcancer: results from tients. Analysis of established biomarkers in BC is a phaseIbstudy. J Clin Oncol. 2020;38(17):1887. essentialfor allpatients where treatment is available. 9. Cortes J, Kim S, Chung W, et al. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients Currently, it is still recommended to perform biopsies (Pts) with HER2+ metastatic breast cancer (mBC): Results of new lesions in metastatic patients. The hope is that of the randomized phase III DESTINY-Breast03 study. Ann with the increasing number of studies, cell free DNA Oncol. 2021;32(suppl_5):S1283–S346. https://doi.org/10. based mutation testing will demonstrate its reliability 1016/annonc/annonc741.abstrLBA1. and robustness and at least partially replace the more 10. Manich SC, O’Shaughnessy J, Aftimos PG, et al. Primary invasive tissue testing. With the available novel tech- outcome of the phase III SYD985.002/TULIP trial compar- nologies, the hope is to identify an increasing number ing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive lo- of treatment targets and agents which are urgently cally advanced or metastatic breast cancer. Ann Oncol. needed especially for TNBC. 2021;32(suppl_5):S1283–S346. https://doi.org/10.1016/ Funding Open access funding provided by Medical University annonc/annonc741. abstr LBA15. of Graz. 11. Banerji U, van Herpen CML, Saura C, et al. Trastuzumab duocarmazine in locally advanced and metastatic solid Conflict of interest E.V. Klocker received congress fees from tumours and HER2-expressing breast cancer: a phase 1 Pierre Fabre, Roche and Daiichi-Sankyo and congress fees dose-escalation and dose-expansion study. Lancet Oncol. from Novartis and AstraZeneca. M. Balic received honoraria 2019;20(8):1124–35. and congress fees from Amgen, AstraZeneca, Bayer, Celgene, 12. Bose R, Kavuri SM, Searleman AC, et al. Activating HER2 Daichii Sankyo, Pfizer, EliLilly, Novartis, Roche, MSD, Sam- mutations in HER2 gene amplification negative breast sung, Pierre Fabre and Seagen. G. Steger declares that he has cancer. Cancer Discov. 2013;3(2):224–37. no competing interests. 13. HymanDM, Piha-Paul SA, WonH,et al. HERkinase inhi- bition in patients with HER2- and HER3-mutant cancers. Open Access This article is licensed under a Creative Com- Nature. 2018;554(7691):189–94. mons Attribution 4.0 International License, which permits 14. Dey N, Williams C, Leyland-Jones B, et al. A critical role use, sharing, adaptation, distribution and reproduction in for HER3 in HER2-amplified and non-amplified breast any medium or format, as long as you give appropriate credit cancers: function of a kinase-dead RTK. Am J Transl Res. to the original author(s) and the source, provide a link to 2015;7(4):733–50. the Creative Commons licence, and indicate if changes were 15. Pascual T, Oliveira M, Ciruelos E, et al. SOLTI-1805 TOT- made. The images or other third party material in this article HER3 study concept: a window-of-opportunity trial of are included in the article’s Creative Commons licence, unless Patritumab Deruxtecan, a HER3 directed antibody drug indicated otherwise in a credit line to the material. If material conjugate, in patients with early breast cancer. Front Oncol. is not included in the article’s Creative Commons licence and 2021;11:638482. your intended use is not permitted by statutory regulation or 16. Kogawa T, Yonemori K, Masuda N, etal. Singleagentactivity exceeds the permitted use, you will need to obtain permis- of U3-1402, a HER3-targeting antibody-drug conjugate, in sion directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. Molecular profiling in breast cancer K short review breast cancer patients: Phase 1 dose escalation study. J Clin Primary results from IPATunity130 Cohort A. Cancer Res. Oncol. 2018;36(15_suppl):2512–2512. 2021;81(4_Suppl):abstr GS3-04. SABCS20-GS3-04. 17. Janne PA, Baik C, Su WC, et al. Efficacy and safety of 32. Robson M, Im SA, Senkus E, et al. Olaparib for metastatic Patritumab Deruxtecan (HER3-DXd) in EGFR inhibitor-re- breast cancer in patients with a Germline BRCA mutation. sistant, EGFR-mutated non-small cell lung cancer. Cancer NEngl J Med. 2017;377(6):523–33. Discov. 2021; 2022 Jan;12(1):74–89. 33. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with 18. Burstein MD, Tsimelzon A, Poage GM, et al. Compre- advanced breast cancer and a Germline BRCA mutation. hensive genomic analysis identifies novel subtypes and NEngl J Med. 2018;379(8):753–63. targets of triple-negative breast cancer. Clin Cancer Res. 34. Tomao F, Bardhi E, Di Pinto A, et al. Parp inhibitors as 2015;21(7):1688–98. maintenance treatment in platinum sensitive recurrent 19. Traina TA, Miller K, Yardley DA, et al. Enzalutamide for the ovarian cancer: an updated meta-analysis of randomized treatment of androgen receptor-expressing triple-negative clinical trials according to BRCA mutational status. Cancer breastcancer. J Clin Oncol. 2018;36(9):884–90. TreatRev. 2019;80:101909. 20. BardiaA,HurvitzSA,TolaneyAM,etal. Sacituzumabgovite- 35. Fasching PA, Link T, Hauke J, Seither F, Jackisch C, Klare P, can in metastatic triple-negative breast cancer. N Engl J et al. Neoadjuvant paclitaxel/olaparib in comparison to Med. 2021;384:1529–41. paclitaxel/carboplatinum in patients with HER2-negative 21. TurnerNC,KingstonB,KilburnLS,etal. Circulatingtumour breast cancer and homologous recombination deficiency DNA analysis to direct therapy in advanced breast cancer (GeparOLA study). Ann Oncol. 2021;32(1):49–57. (plasmaMATCH): a multicentre, multicohort, phase 2a, 36. Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, platformtrial. LancetOncol. 2020;21(10):1296–308. Gazinska P, et al. Carboplatin in BRCA1/2-mutated and 22. Rugo HS, Lerebours F, Ciruelos E, et al. Alpelisib plus ful- triple-negative breast cancer BRCAness subgroups: the vestrant in PIK3CA-mutated, hormone receptor-positive TNT Trial. NatMed. 2018;24(5):628–37. advanced breast cancer after a CDK4/6 inhibitor (BYLieve): 37. Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, one cohort of a phase 2, multicentre, open-label, non- Rastogi P, et al. Adjuvant Olaparib for patients with comparativestudy. LancetOncol. 2021;22(4):489–98. BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 23. Fribbens C, O’Leary B, Kilburn L, et al. Plasma ESR1 2021;384(25):2394–405. mutations and the treatment of estrogen receptor-positive 38. Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab- advancedbreastcancer. J Clin Oncol. 2016;34(25):2961–8. paclitaxel as first-line treatment for unresectable, locally 24. O’Leary B, Cutts RJ, Liu Y, et al. The genetic landscape and advanced or metastatic triple-negative breast cancer (IM- clonal evolution of breast cancer resistance to Palbociclib passion130): updated efficacy results from a randomised, plus Fulvestrant in the PALOMA-3 trial. Cancer Discov. double-blind, placebo-controlled, phase 3 trial. Lancet 2018;8(11):1390–403. Oncol. 2020;21(1):44–59. 25. Razavi P, Chang MT, Xu G, et al. The genomic landscape of 39. Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab endocrine-resistant advanced breast cancers. Cancer Cell. plus chemotherapy versus placebo plus chemotherapy 2018; 34(3):427–438.e6. for previously untreated locally recurrent inoperable or 26. AndréF,CiruelosE,RubovszkyG,etal. AlpelisibforPIK3CA- metastatic triple-negative breast cancer (KEYNOTE-355): mutated, hormone receptor-positive advanced breast can- a randomised, placebo-controlled, double-blind, phase 3 cer. NEngl J Med. 2019;380(20):1929–40. clinical trial. Lancet. 2020;396(10265):1817–28. 27. André F, Ciruelos EM, Juric D, et al. Alpelisib plus ful- 40. Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab vestrant for PIK3CA-mutated, hormone receptor-positive, for early triple-negative breast cancer. N Engl J Med. human epidermal growth factor receptor-2-negative ad- 2020;382(9):810–21. vanced breast cancer: final overall survival results from 41. Mittendorf EA, Zhang H, Barrios CH, etal. Neoadjuvantate- SOLAR-1. Ann Oncol. 2021;32(2):208–17. zolizumab in combination with sequential nab-paclitaxel 28. Lin J, Sampath D, Nannini MA, et al. Targeting activated and anthracycline-based chemotherapy versus placebo Akt with GDC-0068, a novel selective akt inhibitor that is and chemotherapy in patients with early-stage triple-nega- efficacious in multiple tumor models. Clin Cancer Res. tive breast cancer (IMpassion031): a randomised, double- 2013;19(7):1760–72. blind, phase3 trial. Lancet. 2020;396(10257):1090–100. 29. Jones RH, CasbardA, Carucci M, etal. Fulvestrantplus capi- Publisher’s Note Springer Nature remains neutral with regard vasertib versus placebo after relapse or progression on an to jurisdictional claims in published maps and institutional aromatase inhibitor in metastatic, oestrogen receptor-pos- affiliations. itive breast cancer (FAKTION): a multicentre, randomised, controlled, phase2 trial. LancetOncol. 2020;21(3):345–57. 30. Kim SB, Dent R, Im SA, et al. Ipatasertib plus pacli- taxel versus placebo plus paclitaxel as first-line therapy for 7 For latest news from interna- metastatic triple-negative breast cancer (LOTUS): a mul- ticentre, randomised, double-blind, placebo-controlled, tional oncology congresses see: phase2 trial. LancetOncol. 2017;18(10):1360–72. http://www.springermedizin.at/ 31. Dent R, Kim SB, Oliveira M, et al. Double-blind memo-inoncology placebo-controlled randomized phase III trial evalu- ating first-line ipatasertib combined with paclitaxel for -PIK3CA/AKT1/PTEN-altered locally advanced un- resectable or metastatic triple-negative breast cancer: K Molecular profiling in breast cancer

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Feb 15, 2022

Keywords: oncology; medicine/public health, general

References